vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and REGIS CORP (RGS). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $57.1M, roughly 1.7× REGIS CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 0.8%, a 27.6% gap on every dollar of revenue. On growth, REGIS CORP posted the faster year-over-year revenue change (22.3% vs 17.7%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $891.0K). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 7.8%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
REGIS CORPRGSEarnings & Financial Report
Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.
DVAX vs RGS — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $57.1M |
| Net Profit | $26.9M | $456.0K |
| Gross Margin | — | — |
| Operating Margin | 22.4% | 10.8% |
| Net Margin | 28.4% | 0.8% |
| Revenue YoY | 17.7% | 22.3% |
| Net Profit YoY | 53.0% | -94.0% |
| EPS (diluted) | $0.21 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.1M | ||
| Q3 25 | $94.9M | $59.0M | ||
| Q2 25 | $95.4M | $60.4M | ||
| Q1 25 | $68.2M | $57.0M | ||
| Q4 24 | $72.0M | $46.7M | ||
| Q3 24 | $80.6M | $46.1M | ||
| Q2 24 | $73.8M | $49.4M | ||
| Q1 24 | $50.8M | $49.2M |
| Q4 25 | — | $456.0K | ||
| Q3 25 | $26.9M | $1.4M | ||
| Q2 25 | $18.7M | $116.5M | ||
| Q1 25 | $-96.1M | $250.0K | ||
| Q4 24 | $7.0M | $7.6M | ||
| Q3 24 | $17.6M | $-853.0K | ||
| Q2 24 | $11.4M | $91.2M | ||
| Q1 24 | $-8.7M | $-2.3M |
| Q4 25 | — | 10.8% | ||
| Q3 25 | 22.4% | 10.0% | ||
| Q2 25 | 15.1% | 12.1% | ||
| Q1 25 | -34.7% | 8.8% | ||
| Q4 24 | -2.3% | 11.8% | ||
| Q3 24 | 12.5% | 4.6% | ||
| Q2 24 | 7.0% | — | ||
| Q1 24 | -35.0% | 8.3% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | 28.4% | 2.3% | ||
| Q2 25 | 19.6% | 192.9% | ||
| Q1 25 | -141.0% | 0.4% | ||
| Q4 24 | 9.8% | 16.4% | ||
| Q3 24 | 21.8% | -1.9% | ||
| Q2 24 | 15.4% | 184.7% | ||
| Q1 24 | -17.2% | -4.7% |
| Q4 25 | — | $0.16 | ||
| Q3 25 | $0.21 | $0.49 | ||
| Q2 25 | $0.14 | $43.67 | ||
| Q1 25 | $-0.77 | $0.08 | ||
| Q4 24 | $0.07 | $2.71 | ||
| Q3 24 | $0.12 | $-0.36 | ||
| Q2 24 | $0.08 | $38.40 | ||
| Q1 24 | $-0.07 | $-1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $18.4M |
| Total DebtLower is stronger | — | $113.3M |
| Stockholders' EquityBook value | $534.1M | $188.7M |
| Total Assets | $946.5M | $588.3M |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.4M | ||
| Q3 25 | $160.2M | $16.6M | ||
| Q2 25 | $99.1M | $17.0M | ||
| Q1 25 | $51.7M | $13.3M | ||
| Q4 24 | $95.9M | $10.2M | ||
| Q3 24 | $119.3M | $6.3M | ||
| Q2 24 | $112.5M | $10.1M | ||
| Q1 24 | $132.0M | $5.9M |
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
| Q4 25 | — | $188.7M | ||
| Q3 25 | $534.1M | $187.6M | ||
| Q2 25 | $494.2M | $185.6M | ||
| Q1 25 | $530.9M | $68.6M | ||
| Q4 24 | $596.8M | $66.7M | ||
| Q3 24 | $681.4M | $56.4M | ||
| Q2 24 | $642.8M | $56.8M | ||
| Q1 24 | $618.5M | $-35.8M |
| Q4 25 | — | $588.3M | ||
| Q3 25 | $946.5M | $592.1M | ||
| Q2 25 | $918.4M | $599.0M | ||
| Q1 25 | $945.9M | $511.2M | ||
| Q4 24 | $986.3M | $530.1M | ||
| Q3 24 | $1.1B | $508.9M | ||
| Q2 24 | $1.0B | $530.5M | ||
| Q1 24 | $986.6M | $543.7M |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $1.7M |
| Free Cash FlowOCF − Capex | $32.6M | $891.0K |
| FCF MarginFCF / Revenue | 34.4% | 1.6% |
| Capex IntensityCapex / Revenue | 1.3% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.26× | 3.65× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.7M | ||
| Q3 25 | $33.8M | $2.3M | ||
| Q2 25 | $23.4M | $6.8M | ||
| Q1 25 | $-19.6M | $6.2M | ||
| Q4 24 | $53.0M | $2.1M | ||
| Q3 24 | $19.5M | $-1.3M | ||
| Q2 24 | $10.7M | $5.1M | ||
| Q1 24 | $-16.7M | $-277.0K |
| Q4 25 | — | $891.0K | ||
| Q3 25 | $32.6M | $1.9M | ||
| Q2 25 | $22.0M | $6.2M | ||
| Q1 25 | $-23.6M | $5.9M | ||
| Q4 24 | $49.5M | $1.7M | ||
| Q3 24 | $18.1M | $-1.4M | ||
| Q2 24 | $9.9M | $5.1M | ||
| Q1 24 | $-17.4M | $-326.0K |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 34.4% | 3.2% | ||
| Q2 25 | 23.0% | 10.3% | ||
| Q1 25 | -34.6% | 10.3% | ||
| Q4 24 | 68.8% | 3.6% | ||
| Q3 24 | 22.5% | -3.0% | ||
| Q2 24 | 13.5% | 10.3% | ||
| Q1 24 | -34.3% | -0.7% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 1.5% | 0.9% | ||
| Q1 25 | 5.8% | 0.6% | ||
| Q4 24 | 4.8% | 0.9% | ||
| Q3 24 | 1.7% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 1.5% | 0.1% |
| Q4 25 | — | 3.65× | ||
| Q3 25 | 1.26× | 1.68× | ||
| Q2 25 | 1.25× | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | 7.52× | 0.28× | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | 0.06× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
